b
r
c
current
knowledg
idiopath
pneumonia
syndrom
ip
predat
improv
specif
diagnosi
ip
advanc
hematopoiet
cell
transplant
hct
critic
care
practic
studi
describ
updat
incid
risk
factor
outcom
ip
perform
retrospect
cohort
studi
adult
underw
allogen
hct
fred
hutchinson
cancer
research
center
n
ip
defin
use
nation
heart
lung
blood
institut
consensu
definit
multilobar
airspac
opac
chest
imag
absenc
lower
respiratori
tract
infect
hypoxemia
describ
ip
incid
mortal
within
day
hct
examin
condit
intens
nonmyeloabl
versu
myeloabl
highdos
total
bodi
irradi
tbi
versu
myeloabl
lowdos
tbi
ip
risk
factor
timetoev
analysi
use
cox
model
control
age
transplant
hla
match
stem
cell
sourc
pretranspl
lung
function
score
combin
measur
impair
forc
expiratori
volum
first
second
fev
diffus
capac
carbon
monoxid
dlco
among
hct
recipi
fulfil
ip
criteria
within
day
individu
develop
ip
like
blacknonhispan
versu
racial
group
sever
pulmonari
impair
otherwis
similar
particip
without
ip
adjust
model
myeloabl
condit
highdos
tbi
associ
increas
risk
ip
hazard
ratio
confid
interv
thirtyon
patient
ip
die
within
first
day
hct
patient
die
within
day
hct
contrast
among
patient
acquir
ip
first
day
die
within
day
hct
die
within
day
hct
find
suggest
although
incid
ip
may
declin
remain
associ
posttranspl
mortal
futur
studi
focu
earli
detect
identifi
patholog
mediat
ip
facilit
time
target
therapi
suscept
lung
injuri
posthct
term
idiopath
pneumonia
syndrom
ip
use
defin
spectrum
noninfecti
diffus
lung
injuri
occur
follow
hematopoiet
cell
transplant
hct
previou
report
estim
ip
develop
hct
recipi
case
fatal
first
day
posttranspl
howev
estim
predat
improv
diagnost
specif
ip
refin
transplant
practic
advanc
support
critic
care
led
overal
improv
transplant
outcom
ip
criteria
includ
evid
widespread
alveolar
injuri
symptom
sign
pneumonia
absenc
activ
lower
respiratori
tract
infect
use
updat
molecular
techniqu
detect
infecti
pathogen
lung
seo
et
al
shown
half
patient
diagnos
ip
viru
detect
bronchoalveolar
lavag
bal
sampl
signific
virus
pathogen
pneumonia
remain
unclear
emerg
evid
suggest
least
case
human
herpesviru
virus
may
lead
lung
injuri
rais
plausibl
concern
ip
may
misdiagnos
earlier
studi
ip
encompass
spectrum
clinic
present
thought
result
divers
lung
insult
previous
defin
risk
factor
develop
ip
allogen
hct
includ
condit
intens
total
bodi
irradi
dose
tbi
highgrad
acut
graftversushost
diseas
gvhd
advanc
age
transplant
indic
howev
increas
util
reducedintens
condit
regimen
improv
prevent
treatment
acut
gvhd
introduct
umbil
cord
blood
stem
cell
improv
prevent
control
infecti
complic
chang
hctrecipi
exposur
may
alter
spectrum
lung
injuri
patient
undergon
allogen
hct
perform
retrospect
cohort
studi
contemporari
cohort
patient
underw
allogen
hct
rigor
adjud
ip
statu
herein
report
updat
incid
risk
factor
outcom
ip
hypothes
condit
regimen
intens
tbi
dose
would
remain
signific
risk
factor
develop
ip
explor
risk
ip
relat
recipi
transplant
factor
final
given
advanc
support
critic
care
practic
hypothes
mortal
patient
develop
ip
would
lower
compar
earlier
studi
perform
retrospect
cohort
studi
adult
underw
allogen
hct
fred
hutchinson
cancer
research
center
fhcrc
seattl
washington
includ
first
allogen
hct
perform
patient
studi
period
patient
younger
year
adult
receiv
autolog
graft
exclud
fhcrc
institut
review
board
approv
analysi
patient
receiv
condit
regimen
follow
infus
hematopoiet
stem
cell
accord
local
protocol
although
condit
regimen
vari
myeloabl
condit
regimen
gener
contain
busulfan
either
cyclophosphamid
fludarabin
treosulfan
fludarabin
plu
lowdos
tbi
gray
gy
cyclophosphamid
without
fludarabin
plu
highdos
tbi
gy
tbi
dose
fraction
schedul
tailor
patient
condit
protocol
gener
institut
standard
treatment
protocol
deliv
total
dose
twicedaili
fraction
gy
consecut
day
total
dose
twicedaili
fraction
gy
consecut
day
dose
rate
cgymin
reducedintens
nonmyeloabl
regimen
contain
gy
tbi
without
fludarabin
patient
receiv
immunosuppress
drug
usual
calcineurin
inhibitor
mycophenol
mofetil
gvhd
prophylaxi
antimicrobi
prophylaxi
consist
levofloxacin
neutropenia
absolut
neutrophil
count
anc
cellsmm
acyclovir
trimethoprimsulfamethoxazol
fluconazol
moldact
triazol
preemptiv
therapi
use
cytomegaloviru
cmv
basi
weekli
antigen
dna
test
pulmonari
symptom
respiratori
specimen
sent
microbiolog
evalu
describ
acut
gvhd
diagnos
clinic
treat
physician
grade
accord
previous
describ
criteria
ip
defin
use
nation
heart
lung
blood
institut
consensu
definit
requir
new
multilobar
airspac
opac
chest
imag
absenc
lower
respiratori
tract
infect
abnorm
pulmonari
physiolog
standard
local
practic
broad
panel
microbiolog
studi
sent
bal
sampl
respiratori
tract
specimen
obtain
via
bal
lung
biopsi
perform
submit
cytolog
patholog
analys
convent
stain
cultur
bacteria
fungi
mycobacteria
nocardia
virus
shell
viral
centrifug
viral
cultur
cmv
respiratori
syncyti
viru
rsv
direct
fluoresc
antibodi
test
legionella
pneumocysti
jiroveci
cmv
rsv
parainfluenza
viru
type
adenoviru
serum
bal
routin
test
aspergillu
galactomannan
index
use
biorad
platelia
assay
hercul
ca
addit
multiplex
quantit
reversetranscriptas
pcr
panel
use
detect
respiratori
virus
includ
influenza
influenza
b
rsv
parainfluenza
viru
type
adenoviru
human
metapneumoviru
coronaviru
rhinoviru
bocaviru
invas
fungal
infect
defin
accord
european
organ
research
treatment
cancermycos
studi
group
criteria
bacteri
pneumonia
diagnos
bal
cultur
grew
colonyform
unit
per
millilit
pathogen
gramposit
cocci
number
gramneg
rod
pathogen
isol
set
compat
radiograph
chang
viral
pneumonia
diagnos
pcr
copiesml
pneumoniacaus
respiratori
virus
isol
known
human
pathogen
may
play
role
pathogenesi
ip
retrospect
test
remnant
clinic
bal
sampl
avail
local
biorepositori
n
particip
identifi
pcrcopi
per
microlit
censor
date
bronchoscopi
n
potenti
ip
case
meet
radiograph
criteria
indetermin
bal
result
perform
comprehens
manual
chart
review
consid
factor
respons
medic
therapi
relaps
serial
bal
result
autopsi
result
ip
case
requir
sustain
progress
hypoxemia
unrespons
antibiot
diuret
defin
peripher
capillari
oxygen
satur
spo
increas
baselin
oxygen
requir
liter
per
minut
lpm
new
increasedfrombaselin
aa
differ
arteri
blood
gase
ip
onset
defin
day
chest
imag
first
reveal
multilobar
infiltr
note
chest
imag
potenti
ip
case
review
expert
event
disagr
third
achiev
consensu
adjud
cohort
supplementari
tabl
patient
ip
compar
patient
without
ip
use
wilcoxon
ranksum
test
continu
variabl
pearson
chisquar
test
categori
factor
probabl
ip
estim
cumul
incid
incid
rate
compar
cumul
incid
predefin
group
use
nelsonaalen
curv
logrank
test
examin
sever
potenti
ip
risk
factor
use
bivari
cox
regress
host
factor
interest
includ
patient
age
sex
raceethn
indic
transplant
recipi
cmv
serostatu
lung
function
score
lf
combin
measur
impair
fev
dlco
model
condit
intens
nonmyeloabl
myeloabl
lowdos
tbi
gy
myeloabl
highdos
tbi
gy
consist
previou
analysi
ip
addit
transplant
characterist
includ
hematopoiet
stem
cell
sourc
cord
blood
versu
peripher
blood
bone
marrow
transplant
type
hlamatch
relat
unrel
hlamismatch
unrel
donor
cmv
serostatu
use
multivari
cox
regress
model
examin
associ
primari
exposur
interest
condit
intens
develop
ip
control
potenti
confound
variabl
model
chosen
priori
base
previou
data
host
factor
transplant
characterist
associ
increas
risk
ip
develop
ip
rare
outcom
cohort
avoid
introduc
bia
overfit
parsimoni
variabl
inclus
control
patient
age
transplant
transplant
type
hla
match
versu
unmatch
stem
cell
sourc
cord
blood
versu
altern
sourc
pretranspl
lf
transplant
type
stem
cell
sourc
dichotom
hypothes
clinic
relev
categori
lf
model
continu
variabl
sever
grade
iii
iv
acut
gvhd
includ
final
model
sever
gvhd
like
myeloabl
condit
may
mediat
relationship
condit
intens
ip
sensit
analysi
adjust
sever
acut
gvhd
occur
ip
onset
timedepend
covari
final
race
ad
covari
separ
sensit
analysi
predomin
white
cohort
blacknonhispan
raceethn
colinear
hla
match
receipt
umbil
cord
stem
cell
therefor
includ
primari
model
examin
associ
ip
overal
surviv
hct
use
cox
regress
model
ip
timedepend
exposur
bivari
cox
regress
model
use
assess
factor
associ
postip
mortal
day
day
hct
factor
chosen
base
associ
posttranspl
respiratori
failur
allcaus
mortal
examin
schoenfeld
residu
assess
proport
hazard
assumpt
timetoev
model
violat
found
adjust
made
multipl
comparison
consid
p
valu
less
statist
signific
analys
perform
use
stata
version
statacorp
lp
colleg
station
tx
cohort
consist
adult
underw
allogen
hct
fhcrc
bal
perform
patient
develop
pulmonari
infiltr
among
patient
pulmonari
infect
identifi
specimen
collect
patient
exclud
patient
possibl
ip
case
comprehens
chart
review
addit
patient
exclud
ip
group
presum
cardiogen
pulmonari
edema
respons
diuret
rapid
respons
empir
antibiot
presenc
extrapulmonari
infecti
sourc
ultim
patient
fulfil
ip
criteria
median
followup
time
day
rang
day
number
ip
case
similar
across
calendar
year
throughout
studi
period
supplementari
figur
bold
p
valu
repres
statist
signfic
differ
without
ip
factor
repres
column
correspond
p
valu
defin
p
statist
signific
high
risk
defin
activ
de
novo
relaps
acut
myelogen
leukemia
md
refractori
anemia
excess
blast
excess
blast
transform
myeloprolif
disord
acut
lymphoblast
leukemia
cll
nonhodgkin
lymphoma
hd
mm
regardless
statu
acceler
phase
blastic
crisi
cml
tumor
renal
cell
carcinoma
low
risk
defin
nonmalign
diseas
includ
aplast
anemia
immunodefici
syndrom
diseas
mention
unknown
diseas
statu
remiss
except
mm
cml
chronic
phase
md
refractori
anemia
without
ring
sideroblast
lung
function
score
pretranspl
lf
repres
sum
fev
dlco
impair
score
individu
develop
ip
like
receiv
myeloabl
condit
includ
highdos
tbi
pretranspl
lung
function
impair
raciallyethn
blacknonhispan
tabl
cohort
predominantli
whitenonhispan
patient
black
race
like
receiv
hlamismatch
umbil
cord
stem
cell
therefor
like
condit
regimen
includ
highdos
tbi
versu
cumul
incid
ip
day
allogen
hct
incid
rate
case
per
personday
figur
among
patient
ip
acut
gvhd
onset
ip
addit
patient
diagnos
gvhd
follow
ip
diagnosi
unadjust
cumul
incid
curv
stratifi
condit
regimen
show
signific
differ
cumul
incid
ip
patient
receiv
myeloabl
versu
nonmyeloabl
condit
figur
howev
receiv
myeloabl
regimen
highdos
tbi
gy
compar
receiv
either
myeloabl
condit
lowdos
tbi
nonmyeloabl
condit
associ
increas
cumul
incid
ip
primari
analysi
myeloabl
condit
highdos
tbi
gy
associ
increas
risk
ip
bivari
fulli
adjust
model
adjust
hazard
ratio
hr
confid
interv
ci
tabl
increas
risk
ip
observ
patient
receiv
myeloabl
condit
lowdos
tbi
compar
nonmyeloabl
regimen
fulli
adjust
cox
model
baselin
lung
impair
associ
ip
develop
wherea
age
transplant
indic
previous
identifi
ip
risk
factor
myeloabl
condit
highdos
tbi
remain
associ
increas
risk
ip
adjust
sever
acut
gvhd
hr
ci
addit
adjust
raceethn
chang
magnitud
associ
condit
intens
ip
fulli
adjust
model
hr
ci
among
patient
develop
ip
median
time
ip
onset
day
allogen
hct
rang
day
median
time
ip
onset
death
day
rang
day
thirtyon
patient
ip
die
within
first
day
hct
patient
die
within
day
hct
contrast
among
patient
develop
ip
first
day
differ
attribut
condit
cumul
incid
ip
among
allogen
hct
patient
myeloabl
n
versu
nonmyeloabl
n
condit
cumul
incid
rate
ip
day
myeloabl
condit
red
line
nonmyeloabl
blue
line
condit
respect
p
b
differ
attribut
total
bodi
irradi
condit
intens
compar
cumul
incid
ip
among
allogen
hct
patient
nonmyeloabl
blue
line
n
versu
myeloabl
highdos
tbi
red
line
n
versu
myeloabl
condit
lowdos
tbi
green
line
n
versu
versu
respect
p
die
within
day
hct
die
within
day
hct
among
transplant
recipi
die
within
day
hct
die
follow
diagnosi
ip
final
patient
underw
bronchoscopi
pulmonari
infiltr
altern
diagnosi
ip
determin
die
day
hct
figur
develop
ip
associ
increas
risk
death
first
day
posthct
hr
ci
day
hr
ci
baselin
poor
lung
function
acut
respiratori
failur
requir
mechan
ventil
renal
insuffici
hepat
injuri
associ
increas
risk
mortal
follow
ip
tabl
mechan
ventil
initi
patient
median
day
ip
onset
mortal
group
day
posthct
twentyon
ip
case
liber
ventil
patient
requir
resum
mechan
ventil
die
day
everventil
patient
ip
aliv
day
increas
risk
death
day
hct
hr
ci
compar
neverventil
ip
case
notabl
myeloabl
condit
highdos
tbi
associ
increas
risk
death
follow
ip
diagnosi
studi
provid
import
updat
incid
risk
factor
outcom
ip
demonstr
lower
incid
ip
compar
histor
report
may
reflect
advanc
transplant
practic
improv
specif
diagnosi
ip
identifi
myeloabl
condit
highdos
tbi
gy
remain
ip
risk
factor
first
associ
pretranspl
lung
function
impair
risk
ip
develop
observ
lower
mortal
patient
ip
day
hct
compar
previou
cohort
found
mortal
remain
high
observ
confirm
ip
continu
associ
signific
morbid
refin
support
care
advanc
prevent
care
immunerel
toxic
andor
improv
classif
diseas
may
drive
improv
shortterm
surviv
tbi
previous
identifi
ip
risk
factor
studi
suggest
tbi
dose
may
primari
mediat
regimenrel
pulmonari
toxic
although
myeloabl
condit
regimen
use
high
tbi
dose
associ
ip
risk
myeloabl
condit
regimen
lower
tbi
dose
experiment
observ
studi
support
role
tbi
ip
develop
murin
model
demonstr
highdos
irradi
multipl
harm
effect
lung
radiat
caus
damag
lung
endotheli
dna
result
cell
death
acut
lung
injuri
simultan
reduc
toler
lung
injuri
promot
death
alveolar
macrophag
colonyform
cell
import
mediat
pulmonari
damag
repair
addit
total
dose
sever
radiat
paramet
identifi
risk
factor
pathogenesi
pulmonari
toxic
gener
agreement
fraction
tbi
safer
singledos
tbi
respect
ip
therefor
center
other
use
fraction
schedul
role
rate
deliv
tbi
dose
debat
lower
dose
rate
gener
prefer
current
american
societi
radiat
oncolog
guidelin
recommend
dose
rate
gy
per
minut
final
center
practic
lung
shield
techniqu
systemat
reduc
radiat
exposur
lung
potenti
benefit
practic
uncertain
optim
protocol
remain
area
activ
studi
although
studi
specif
design
examin
pretranspl
lung
function
novel
find
associ
baselin
lung
dysfunct
ip
noteworthi
pretranspl
pulmonari
function
test
aid
prognost
identif
individu
greater
risk
posttranspl
complic
mortal
previou
studi
link
impair
dlco
fev
increas
risk
posttranspl
respiratori
failur
allcaus
mortal
togeth
prior
studi
find
warrant
addit
attent
futur
investig
justifi
continu
caution
transplant
patient
sever
reduc
lung
function
pbsc
indic
peripher
blood
stem
cell
bm
bone
marrow
adjust
model
control
condit
regimen
primari
exposur
age
type
transplant
stem
cell
sourc
lung
function
score
lung
function
score
pretranspl
lf
repres
sum
fev
dlco
impair
score
z
adjust
sensit
analysi
previou
report
consid
acut
gvhd
potenti
ip
risk
factor
argu
observ
associ
acut
gvhd
ip
suggest
causal
link
observ
grade
iii
iv
acut
gvhd
remain
highli
associ
ip
adjust
risk
factor
notabl
account
small
amount
observ
relationship
condit
intens
ip
one
interpret
result
condit
intens
mediat
develop
acut
gvhd
ip
explain
high
correl
syndrom
interrel
immun
mechan
gvhd
ip
lend
support
argument
experiment
ip
model
tnfa
ifng
mediat
signal
transduct
cascad
orchestr
noninfecti
lung
inflamm
injuri
model
acut
gvhd
similar
cytokin
dysregul
promot
expans
alloreact
donor
cell
moreov
hypothes
lipopolysaccharid
transloc
intestin
damag
result
condit
toxic
acut
gvhd
may
result
neutrophil
alveol
observ
later
stage
experiment
ip
although
agre
immunemedi
lung
injuri
contribut
develop
ip
studi
suggest
gvhd
account
total
risk
addit
factor
must
involv
pathogenesi
earli
noninfecti
lung
injuri
histor
clinic
outcom
among
patient
ip
convent
hct
uniformli
poor
zhu
et
al
recent
describ
patient
mortal
patient
develop
ip
within
day
hct
studi
cohort
use
similar
diagnost
criteria
analysi
zhu
et
al
median
time
death
follow
diagnosi
day
rang
day
compar
day
cohort
although
may
influenc
longer
followup
studi
believ
provid
evid
recent
improv
support
care
along
advanc
transplant
practic
may
respons
improv
shortterm
mortal
treatment
decis
discret
provid
assess
efficaci
novel
treatment
strategi
aim
studi
howev
note
patient
diagnos
ip
typic
receiv
highdos
system
steroid
mgkg
select
case
refractori
diseas
receiv
addit
etanercept
solubl
tnfabind
protein
mgkg
given
twice
weekli
maximum
dose
despit
improv
shortterm
outcom
mortal
remain
high
firm
conclus
drawn
observ
specul
profound
morbid
result
ip
drive
poor
longterm
recoveri
data
confirm
shortterm
survivor
ip
remain
highrisk
group
allogen
hct
recipi
final
associ
found
need
mechan
ventil
organ
injuri
poor
ip
outcom
consist
result
report
larger
seri
hct
recipi
organ
injuri
like
reflect
overal
ill
sever
necessarili
distinct
patholog
entiti
observ
import
may
aid
physician
counsel
patient
famili
regard
prognosi
studi
sever
limit
singlecent
predominantli
white
sampl
may
limit
generaliz
singlecent
design
allow
uniform
practic
pattern
may
improv
abil
assess
novel
risk
factor
small
number
case
restrict
abil
adjust
complet
differ
patient
without
ip
possibl
residu
confound
exist
howev
larg
cohort
wellcharacter
allogen
hct
recipi
allow
us
make
sever
clinic
relev
observ
despit
rigor
adjud
case
misclassif
ip
remain
possibl
appli
modern
molecular
techniqu
identifi
previous
occult
viral
pathogen
includ
possibl
remain
overestim
incid
ip
convers
patient
ip
might
miss
mild
ill
patient
ill
undergo
invas
diagnost
procedur
reason
incid
ip
might
underestim
current
studi
suggest
although
incid
case
fatal
ip
may
declin
remain
significantli
link
posttranspl
morbid
futur
studi
focu
improv
classif
earli
detect
elucid
pathogen
previous
occult
viral
organ
determin
better
balanc
infecti
noninfecti
hct
pulmonari
complic
critic
studi
serum
biomark
diagnos
ip
noninvas
earlier
stage
diseas
develop
shown
promis
would
signific
treatment
implic
await
prospect
valid
final
understand
patholog
mediat
ip
uniqu
phenotyp
essenti
discoveri
novel
treatment
modal
necessari
improv
longterm
outcom
supplementari
materi
associ
articl
found
onlin
version
